Screener
Xeris Biopharma Holdings, Inc. XERS Total Liabilities & Equity
Total Liabilities & Equity at other companies
Other financials
Where this comes from
Reported directly by Xeris Biopharma Holdings, Inc. in its filing.
Tagged under the XBRL concept us-gaap:LiabilitiesAndStockholdersEquity.
The source filing: Xeris Biopharma Holdings, Inc.’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 4:07 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001867096-26-000065
| Assets | June 30, 2026 / (unaudited) | December 31, 2025 |
|---|---|---|
| Stockholders' (deficit) equity: | ||
| Preferred stock—par value $0.0001, 25,000,000 shares authorized and no shares issued and outstanding as of June 30, 2026 and December 31, 2025 | — | — |
| Common stock—par value $0.0001, 350,000,000 shares authorized as of June 30, 2026 and December 31, 2025; 173,591,637 and 166,215,410 shares issued and outstanding as of June 30, 2026 and December 31, 2025, respectively | 18 | 17 |
| Additional paid in capital | 690,432 | 685,004 |
| Accumulated deficit | (700,174) | (671,307) |
| Accumulated other comprehensive loss | (10) | (25) |
| Total stockholders' (deficit) equity | (9,734) | 13,689 |
| Total liabilities and stockholders' equity | $411,905 | $383,527 |
ITEM 1. FINANCIAL STATEMENTS
FAQ
- What is Xeris Biopharma Holdings, Inc.'s total liabilities & equity?
- Xeris Biopharma Holdings, Inc. (XERS) reported total liabilities & equity of $411.91M in Q2 2026.
- How has Xeris Biopharma Holdings, Inc.'s total liabilities & equity changed year-over-year?
- Xeris Biopharma Holdings, Inc.'s total liabilities & equity increased by 23.1% year-over-year, from $334.69M to $411.91M.
- What is the long-term trend for Xeris Biopharma Holdings, Inc.'s total liabilities & equity?
- Over 5 years (2020 to 2025), Xeris Biopharma Holdings, Inc.'s total liabilities & equity has grown at a 19.2% compound annual growth rate (CAGR), from $159.15M to $383.53M.
- What does total liabilities & equity mean?
- Total assets = total liabilities + total equity. This must always balance — a fundamental accounting identity.
Ask your AI about Xeris Biopharma Holdings, Inc.'s total liabilities & equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude